REDWOOD CITY, Calif.--(BUSINESS WIRE)--Tranquis Therapeutics, a clinical-stage private immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced that members of its management team will participate in the following investor conferences in March 2022:
Stifel CNS Days
Date: Tuesday, March 29, 2022
Time: 3:30 pm ET
Event: Company presentation
SVB Leerink Biopharma Private Company Connect
Date: Tuesday, March 29 – Thursday, March 31, 2022
Event: One-on-one investor meetings
A replay of the Stifel CNS Days corporate presentation will be available on the Tranquis website for 90 days following the presentation.
About Tranquis
Tranquis Therapeutics is a breakthrough biopharmaceutical company focused on developing a portfolio of promising small molecule drugs with a unique mechanism of action, capable of reprogramming dysfunctional myeloid immune cells to revolutionize the management of a broad range of mitochondrial and immune mediated CNS and non-CNS indications and to significantly improve the lives of millions of patients. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapies work by restoring normal mitochondrial biogenesis, cell homeostasis and function, effectively “switching” microglia and monocytes from a dysfunctional to a functional state by targeting master regulators of cell energy metabolism. For more information, visit www.tranquis.com.
